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Background: Interleukin-27 signaling is mediated by the JAK-STAT pathway via activation of STAT1 and STAT3,
which have tumor suppressive and oncogenic activities, respectively. Epithelial–mesenchymal transition (EMT) and
angiogenesis are key processes in carcinogenesis. Although IL-27 has been shown to have potent anti-tumor activity in
various cancer models, the role of IL-27 in EMT and angiogenesis is poorly understood. In this study, we investigated
the role of IL-27 in regulating EMT and angiogenesis through modulation of the STAT pathways in human non-small
cell lung carcinoma (NSCLC) cells.
Methods: STAT activation following IL-27 exposure was measured in human NSCLC cell lines. Expression of epithelial
(E-cadherin, γ-catenin) and mesenchymal (N-cadherin, vimentin) markers were assessed by Western blot analysis.
Production of pro-angiogenic factors (VEGF, IL-8/CXCL8, CXCL5) were examined by ELISA. Cell motility was examined
by an in vitro scratch and transwell migration assays. Selective inhibitors of STAT1 (STAT1 siRNAs) and STAT3 (Stattic)
were used to determine whether both STAT1 and STAT3 are required for IL-27 mediated inhibition of EMT and
secretion of angiogenic factors.
Results: Our results demonstrate that IL-27 stimulation in NSCLC resulted in 1) STAT1 and STAT3 activation in a
JAK-dependent manner, 2) development of epithelial phenotypes, including a decrease in the expression of a
transcriptional repressor for E-cadherin (SNAIL), and mesenchymal marker (vimentin) with a reciprocal increase in the
expression of epithelial markers, 3) inhibition of cell migration, and 4) reduced production of pro-angiogenic factors. STAT1
inhibition in IL-27–treated cells reversed the IL-27 effect with resultant increased expression of Snail, vimentin and the
pro-angiogenic factors. The inhibition of STAT3 activation had no effect on the development of the epithelial phenotype.
Conclusion: IL-27 induces mesenchymal to epithelial transition and inhibits the production of pro-angiogenic factors in a
STAT1–dominant pathway. These findings highlight the importance of STAT1 in repressing lung carcinogenesis and
describe a new anti-tumor mechanism of IL-27.
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Interleukin-27 (IL-27) is a member of the IL-12 cytokine
family known to have both pro-inflammatory and anti-
inflammatory functions [1]. In preclinical models, IL-27
has been shown to have anti-tumor properties in a variety
of malignancies through several mechanisms, including
inhibition of tumor proliferation and angiogenesis [2-8].
IL-27 has attracted interest as an anti-tumor agent be-
cause of its similarities to IL-12, which also demonstrated
ability to suppress tumor growth and elicit tumor specific
immune responses [9]. However, the use of IL-12 as a
single agent has been limited by its toxicity and poor
response in clinical trials for advanced renal or ovar-
ian cancers necessitating studies in other promising
agents [9,10].
IL-27 elicits its effects through activation of both STAT1
and STAT3, which have opposing roles in carcinogenesis
[1,2,8,11-15]. Activated STAT1 signaling has tumor sup-
pressive roles by inhibiting angiogenesis, tumor growth
and metastasis as well as promoting apoptosis [12,16]. Al-
ternatively, the STAT3 pathway has been shown to be con-
stitutively activated in many human cancers and has been
implicated in oncogenic transformation and progression
[17-21]. IL-27 is a heterodimeric molecule, composed of
Epstein-Barr virus-induced gene 3 (EBI3) and p28 sub-
units, that is expressed by activated antigen presenting
cells [22]. The intracellular component of its receptor,
comprised of glycoprotein 130 (gp130) and WSX-1 (also
known as IL-27Rα or TCCR), associates with cytoplasmic
protein kinases such as JAKs (Janus Activated Kinases)
that mediate cytokine signaling [1]. The JAK-Signal Trans-
ducer and Activator of Transcription (STAT) signaling
pathway, which was initially identified as a critical process
in normal cellular processes, has also been implicated in
tumor initiation and malignant progression. The STAT
transcriptional factors, which are phosphorylated by the
JAKs, dissociate from the receptor and dimerize followed
by nuclear translocation [23].
Epithelial-mesenchymal transition (EMT) is an evolu-
tionarily conserved process in which cells undergo con-
version from an epithelial to mesenchymal phenotype
whereby cells develop loose cell-cell interactions and be-
come motile [24]. The importance of EMT in driving
carcinogenesis has been shown in lung, breast, prostate,
pancreatic, and liver cancers [25,26].
IL-27 mediated inhibition of angiogenesis is a known
anti-tumor mechanism in various malignancies [3,5]. Al-
though a study showed that either over-expression or
treatment with recombinant IL-27 led to anti-tumor ac-
tivity on murine and human lung cancer cells, there is
limited insight on the mechanism that modulates EMT
and angiogenesis [27]. Furthermore, the mechanisms by
which IL-27 plays a role in modulation of EMT and angio-
genesis in NSCLC through the STAT pathways have notbeen studied. On this basis and given the fact that IL-27
regulates STAT transcriptional factors (STAT1 and STAT3)
that possess opposing activities in cancer, the impact of this
cytokine on lung carcinogenesis was investigated. Here, we
report that IL-27 promotes the expression of epithelial
markers, inhibits cell migration and the production of an-
giogenic factors in human NSCLC through a STAT1 dom-
inant pathway. To our knowledge, the antitumor activity of
IL-27 through a STAT1 dependent pathway has not been
previously described.
Materials and methods
Cell lines and culture
Human NSCLC cell lines (A549, H2122, H1703, H292,
H1437, H460, H1650, and H358) were obtained from
the American Type Culture Collection (Rockville, MD).
The H157 cell line was obtained from the National Can-
cer Institute (Bethesda, MD). Cells were verified by
genotyping and tested for Mycoplasma. The cancer cells
lines were maintained in RPMI-1640 with L-glutamine
(Hyclone, Logan, UT) supplemented with 5% fetal bovine
serum (FBS; Gemini Bio-products, West Sacramento, CA)
in a humidified atmosphere of 5% CO2 at 37°C.
Reagents
Recombinant human IL-27 (R&D Systems, Inc,
Minneapolis, MN) was added at a concentration of
50 ng/mL in serum-free medium. JAK inhibitor I (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) binds to the
JAK2 kinase domain and inhibits JAK1, JAK2, and JAK3.
It was reconstituted in DMSO and added at various con-
centrations from 1-100 nM in serum-free medium. STAT3
inhibitor V, Stattic (Santa Cruz Biotechnology, Inc, Santa
Cruz, CA), is a nonpeptidic small molecule that selectively
inhibits the SH2 domain of STAT3, thereby blocking its
phosphorylation and dimerization. It was dissolved in
DMSO and used at a concentration of 7.5 nM in serum-
free medium. Opti-MEM I Reduced Serum-Medium and
Lipofectamine 2000 reagents (Invitrogen, Carlsbad, CA)
were utilized for transfection.
Flow cytometry
A549 cells were stained with anti-human IL-27 Rα/WSX-
1/TCCR-PE or isotype control (R&D systems, Minneapolis,
MN) for 30 min at room temperature and analyzed by
FACSCalibur (BD, San Jose, CA). FACS data were analyzed
using Flowjo software (Treestar, Ashland, OR).
Transfection of STAT1 small interfering RNA into A549 cells
Cells were seeded in 6-well plates and grown to 40-50%
confluence at the time of transfection. For each sample,
2.5 μL of siRNA (10 μM) was diluted in 200 μL of Opti-
MEM I. Two different constructs of STAT1 siRNA (Cell
Signaling Technology, Danvers, MA) were used to inhibit
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CA) was used as a control siRNA. The sequences for the
STAT1 siRNAI and STAT1 siRNAII are 5’-CGAGAGCU
GUCUAGGUUAAC-3' and 5'- GGGCAUCAUGCAUCU
UACU-3', respectively. Similarly, 2.5 μL of Lipofectamine
2000 was diluted in 200 μL of Opti-MEM I. After 5 mi-
nutes of incubation at room temperature, the diluted olig-
omers were combined with the diluted Lipofectamine
2000 and incubated for 30 minutes at room temperature.
The oligomer-Lipofectamine 2000 complexes were then
added to each well containing the cells and medium and
mixed gently. The cells were then incubated at 37°C in a
CO2 incubator for 6 hours after which the wells were
washed and further cultured for 18 hours after replaced
with serum-free medium. The cells were then treated with
IL-27 and/or Stattic per experimental design.
Western blot
Cell lysates were prepared with RadioImmunoPrecipi-
tation Assay (RIPA) buffer (PBS, 1% NP-40, 0.5% Na-
deoxycholate, 0.1% SDS) containing protease inhibitors
on ice after washing with PBS and were centrifuged at
13,000 rpm for 20 minutes at 4°C. Protein concentra-
tions of cell lysates were measured by BCA assay and up
to 20 μg of total protein were used for each SDS-PAGE.
Western blot was performed after transferring SDS-
PAGE gels to Amersham Hybond-ECL membranes (GE
Healthcare, Piscataway, NJ). After incubation with 5% non-
fat milk or BSA in TBST (10 mM Tris, pH 8.0, 150 mM
NaCl, 0.5% Tween 20) for 1 hour at room temperature,
the membrane was incubated with antibodies against
phosphorylated-STAT1 (Tyr 701,1:1000), total-STAT1
(1:1000), phosphorylated-STAT3 (Tyr 705, 1:1000 dilu-
tion), total-STAT3 (1:1000 dilution), Snail (1:1000) (Cell
Signaling Technology, Danvers, MA), and Vimentin
(1:2000) (BD Biosciences, San Jose, CA) at 4°C for
overnight, and N-cadherin (1:5000), γ-catenin (1:7000),
E-cadherin (1:6000), (BD Biosciences, San Jose, CA), and
GAPDH (1:10,000) (Advanced ImmunoChemical, Long
Beach, CA) at room temperature at 1 hour. Mem-
branes were washed three times for 10 min and incubated
with a 1:10,000 dilution of horseradish peroxidase-con
jugated anti-mouse or anti-rabbit antibodies (Santa Cruz
Biotechnology, Dallas, Texas). Blots were washed with
TBST three times and developed with the ECL system
(PerkinElmer, Waltham, MA) according to the manufac-
turer’s protocols.
Enzyme-linked immunosorbent assay (ELISA)
ELISA kits for human vascular endothelial growth factor
(VEGF), IL-8/CXLC8, and CXCL5 were used (R&D Sys-
tems, Minneapolis, MN). Concentrations of human VEGF,
IL-8/CXCL8 and CXCL5 in culture supernatant were
measured by ELISA following kit instructions. Briefly,100 μL of the samples were loaded on the plates and incu-
bated for 2 hours at room temperature. After the plates
were washed with wash buffer (0.05% Tween20 in PBS),
they were incubated with detection antibody for 2 hours
at room temperature. Immunoreactivity was determined
by adding substrate solution and absorbance (450 nm)
was determined by Vmax Kinetic microplate reader (Mo-
lecular Devices, Sunnyvale, CA).
In vitro cell motility assay
Cancer cells were plated in 6-well flat-bottom plates and
allowed to adhere overnight. After serum starvation, cells
were subject to different treatment conditions. Once the
cells reached 90-95% confluence, a 200 μL pipette tip was
used to make a scratch in the monolayer of cells in each
well. The same fields were observed for cell migration
using a phase-contrast microscope and photographed at
various time points for up to 60 hours.
Transwell cell migration assay
Cell migration assay was performed using a 96 well trans-
well chamber (Corning, Corning, NY). Cells were treated
with STAT1 siRNAII (Cell Signaling Technology, Danvers,
MA) for 24 hours and/or Stattic for 1 hour prior to adding
IL-27. At 1 day of IL-27 treatment, 2 × 104 cells in 75 ul
were added to the bottom chamber of a 96-well plate with
8 μm pore size insert. Cells were allowed to transmigrate
into the lower chamber containing 150 ul of RPMI/10%
FBS. The non-migratory cells on the upper chamber sur-
face were removed, and the upper and lower chambers
were washed with PBS. After washing, 200 ul of Cell dis-
sociation solution (Cultrex, Kampenhout, Belgium) con-
taining Calcein AM (final 1.67 uM) (Molecular Probes,
Eugene, OR) was added to the bottom chamber before re-
assembling the upper chamber. The plate was incubated at
37°C in CO2 incubator for 1 hour. At the end of incubation,
the upper chamber was removed and the plate was read at
485 nm excitation for excitation and 520 nm for emission
using the FLx800 fluorescence reader (BioTek, Winooski,
Vermont). For maximum cell migration (100%) and back-
ground control, same amount of cells and medium, respect-
ively, were directly added to the bottom chamber.
Migration rate was calculated using the following formula:
migration rate %ð Þ ¼ Mean of fluorescence of testðf wells‐
Mean of f luorescence of background control wellsÞ=
Mean of fluorescence of maximumð migration wells‐Mean
of fluorescence of background control wellsÞg100:
Immunofluorescence
A549 cells were cultured to 40-60% confluence on glass
coverslips (ThermoFisher Scientific, Waltham, MA), al-
lowed to adhere overnight, and placed in serum free
medium for four hours prior to IL-27 exposure for
15 minutes at 37°C. The cells were fixed with 4%
Kachroo et al. Journal of Experimental & Clinical Cancer Research 2013, 32:97 Page 4 of 14
http://www.jeccr.com/content/32/1/97paraformaldehyde (Electron Microscopy Sciences, Hat-
field, PA) for 20 minutes at room temperature and then
permeabilized with methanol for 15 minutes at -20°C.
After blocking with 5% BSA in PBS solution for 1 hour at
room temperature, the coverslips were incubated with pri-
mary antibody (1:100 dilution) overnight at 4°C. The
following day, the coverslips were incubated with
fluorescein-conjugated goat anti-rabbit IgG secondary
antibody (1:50 dilution; Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA) for 30 minutes at room
temperature followed by the addition of a DAPI (4'-6-Dia-
midino-2-phenylindole) nuclear stain (1:2000 dilution) for
2 minutes at room temperature. ProLong Gold antifade re-
agent (Invitrogen) was placed on the coverslip and the cells
were then observed under the microscope. The ImageJ
(Image Processing and Analysis in Java) program was used
to create the merged immunofluorescence images.
Statistics
Statistical significance was determined using the two-tailed
Student’s t test and p values less than 0.05 were considered
significant.
Results
IL-27 activates STAT1 and STAT3 with resultant
translocation to the nucleus in human NSCLC cells
The human lung adenocarcinoma cell line, A549, was
treated with IL-27 at time points from 0.25 to 72 hours
and analyzed for activated or tyrosine phosphorylated
STAT1 (P-STAT1) and STAT3 (P-STAT3) proteins by
Western blot. After addition of IL-27, activation of STAT
proteins was observed within 15 minutes with sustained
activation for up to 72 hours (Figure 1A). Total STAT1
(T-STAT1) and STAT3 (T-STAT3) levels were not signifi-
cantly affected by IL-27 exposure.
To validate this concept in other histological subtypes
of NSCLC, seven additional human lung cancer cell
lines (H1703, H292, H157, H1437, H460, H1650, and
H358) were exposed to IL-27 for 24 hours and P-STAT1
and P-STAT3 protein levels were analyzed by Western
blot. Similar to A549 cells, all cell lines, with the excep-
tion of H460 and H358, demonstrated activation of both
transcriptional factors P-STAT1 and P-STAT3 following
IL-27 stimulation (Figure 1B). Total STAT1 and STAT3
levels were comparable in H157, H1437, H460 and H358
cells. There were increased levels of total STAT1 and
STAT3 in H1703 and H292, while decreased in H358
cells, The basis for differential expression of the total
STATs in response IL-27 stimulation in lung cancer cells
is unclear, but may be related to known underlying mu-
tational heterogeneity of different cancer cell lines [28].
The tyrosine phosphorylated forms of STAT trans-
criptional factors are known to translocate to the
nucleus for regulation of gene transcription [23].Immunofluorescence microscopy further confirmed
STAT1 (Figure 1C) and STAT3 (Figure 1D) protein acti-
vation and nuclear translocation in A549 cells. In the
absence of IL-27, there were no detectable levels of phos-
phorylated STAT1 or STAT3 in A549 cells (upper left,
Figure 1C and 1D). In contrast, IL-27-treated A549 cells
showed phosphorylation of STAT1 and STAT3 following
15 minutes of exposure to IL-27 (upper right, Figure 1C
and 1D), with translocation into the nucleus as demon-
strated by the overlay of FITC and DAPI staining (bottom
right, Figure 1C and 1D).
Next, we tested whether IL-27 treatment affects ex-
pression levels of the IL-27 receptor on A549 cells. FACS
analysis of A549 cells showed that these cells express sub-
stantial amounts of IL-27 receptor (TCCR) on the cell sur-
face (Figure 1E). However, the presence of IL-27 did not
affect expression levels of IL-27 receptor on A549 cells at
24 hours (Figure 1F). Evaluation for IL-27 receptor ex-
pression at earlier time points (15 minutes, 30 minutes,
1 hour, and 2 hours) was not changed by IL-27 stimula-
tion (data not shown). These results demonstrate that
IL-27 activates STAT1 and STAT3 with resultant trans-
location into the nucleus without altering expression
levels of the IL-27 receptor.IL-27-mediated STAT activation requires JAK activation
IL-27 binds a receptor comprised of gp130 and WSX-1,
whose intracellular components associate with cytoplas-
mic protein kinases such as JAKs that mediate cytokine
signaling [1]. Upon ligand binding, activated JAKs phos-
phorylate the receptor and provide docking sites for in-
active STAT monomers. The STAT transcriptional factors
become phosphorylated by the JAKs, dissociate from the
receptor, and dimerize for nuclear translocation [23]. Thus,
the importance of JAK signal transduction in the ability of
IL-27 to activate the STAT1 and STAT3 pathways in hu-
man lung cancer was studied. A549 cells were pre-treated
with the vehicle control (DMSO) or a JAK inhibitor for
1 hour followed by exposure to IL-27 and tyrosine phos-
phorylation of STAT1 and STAT3 proteins was assessed by
Western blot. Pre-treatment with the JAK inhibitor re-
sulted in a dose-dependent inhibition of IL-27-mediated
STAT1 and STAT3 activation (P-STAT) with a slightly in-
creased expression of the total STAT1 at 5, 10, 25, and 50
nM (Figure 2). In addition, the activation of STAT1 and
STAT3 proteins by IL-27 treatment was abolished by pre-
treatment of cells with the JAK inhibitor, with doses of
100 nM and 25 nM, respectively. IL-27 did not alter the ac-
tivation of other pathways, including Akt, STAT5, P38, or
MAPK/ERK between 15 minutes and 1 hour following
treatment of A549 cells (see Additional file 1). These data
indicate that JAK activation is required for IL-27-mediated
STAT1 and STAT3 activation.
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Figure 1 IL-27-mediated activation of STAT1 and STAT3. (A) A549 cells were treated with IL-27 (50 ng/mL) for up to 72 hours. The tyrosine
phosphorylated, or activated, forms of STAT1 and STAT3 (P-STAT1 and P-STAT3) as well as the total amounts of the transcriptional factors (T-STAT1
and T-STAT3) were detected by Western blot. (B) Seven human NSCLC cell lines (H1703, H292, H157, H1437, H460, H1650, and H358) were cultured
with the diluent of IL-27 (0.1% PBS/BSA) or IL-27 (50 ng/mL) for 24 hours and the activated and total amounts of STAT1 and STAT3 proteins were
measured by Western blot. The densitometric measurements of total amounts of STAT1 and STAT3 were taken using Image J1.45o. The values above
the figures represent relative density of the bands normalized to GAPDH. (C-D) A549 cells were treated with IL-27 (50 ng/mL) for 15 minutes, and
stained with anti-tyrosine phosphorylated STAT1 (C) (green) and STAT3 (D) (green) antibodies for immunofluorescence microscopy (50 × magnification).
The cells were counterstained with DAPI (blue). The white arrows indicate cells with nuclear activation of STAT1 or STAT3 by IL-27 treatment. Scale bar,
100 μm. (E) Expression of IL-27 receptor (TCCR) on cultured A549 cells. (F) Expression of IL-27 receptor (TCCR) on A549 cells after treatment with or
without IL-27 (50 ng/mL) for 24 hours.
Kachroo et al. Journal of Experimental & Clinical Cancer Research 2013, 32:97 Page 5 of 14
http://www.jeccr.com/content/32/1/97IL-27 regulates and prevents over-expression of STAT3
through activation of the STAT1 pathway
The specificity of STAT activation is determined by the
presence of the docking sites on the receptor, and STAT1
and STAT3 have been shown to be activated in response to
gp130 receptor activation by various stimuli [29,30]. STAT1
and STAT3 are known to regulate transcription of tar-
get genes playing opposing roles in tumorigenesis [11]. In
order to determine if a dominant STAT pathway becomesactivated by IL-27, we performed selective inhibition of the
STAT1 or STAT3 pathways.
A549 cells were transfected with STAT1 siRNAs for
24 hours prior to IL-27 exposure for 15 or 30 minutes, and
the activated and total forms of STAT1 and STAT3 were
measured by Western blot. The expression of P-STAT1
and T-STAT1 proteins was effectively abolished after treat-
ment with STAT1 siRNA I or STAT1 siRNA II while trans-
fection with control siRNA did not significantly affect the
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Figure 2 JAK-dependent activation of STAT1 and STAT3 by IL-27 treatment. A549 cells were cultured in the presence of JAK inhibitor I (1-100 nM)
for 1 hour prior to IL-27 (50 ng/mL) exposure for 24 hours. The activated and total amounts of STAT1 and STAT3 proteins were detected by Western blot.
The densitometric measurements of total amounts of STAT1 and STAT3 were taken using Image J1.45o. The values above the figures represent relative
density of the bands compared to control DMSO that was set to 1 after normalized to GAPDH.
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should be noted that lost or reduced p-STAT3 was shown
in Figure 3A compared to Figure 1A. This may be due to
the procedure of transfection that has been known to in-
duce cellular stress response [31]. Importantly, inhibition
of STAT1 resulted in a marked reciprocal increase in P-
STAT3 compared to control siRNA-transfected cells. It has
been previously shown that STAT3 is constitutively acti-
vated in A549 cells [32]. Our data suggest that STAT1 pro-
tein appears to play an important role in suppressing the
overexpression of tyrosine phosphorylated STAT3 in hu-
man NSCLC cells.
Given the interdependence of STAT1 and STAT3 activa-
tion following IL-27 stimulation, STAT3 inhibition was
evaluated by adding Stattic, a nonpeptidic small molecule
that inhibits the function of the SH2 domain required for
tyrosine phosphorylation, dimerization and subsequent
nuclear translocation of STAT3 [33]. The STAT3 inhibitor
was added to A549 cells for 1 hour prior to IL-27 exposure
for 15 or 30 minutes and the expression of activated and
total amounts of STAT1 and STAT3 proteins were ana-
lyzed by Western blot. As expected, the expression of P-
STAT3 was markedly reduced by pretreatment of STAT3
inhibitor at both time points of IL-27 treatment without
affecting T-STAT3 (Figure 3B). However, activated or total
amount of STAT1 protein was not significantly changed in
the pre-treated cells with Stattic when compared with un-
treated cells, indicating that inhibition of STAT3 alone
does not have a considerable impact on STAT1 activation.
These results suggest that although IL-27 activates both
STAT1 and STAT3, the regulation and prevention of over-
expressing phosphorylated STAT3 requires the presence
of activated STAT1 in NSCLC cells.IL-27 induces an epithelial phenotype in lung cancer cells
through STAT1 activation
A fundamental event during EMT is the loss of cell po-
larity, resulting in transition of polarized epithelial cells
into mobile mesenchymal cells [34]. To evaluate the
phenotypic changes of NSCLC cells in response to dif-
ferential STAT1 and STAT3 activation following IL-27
treatment, changes in morphologic features of lung can-
cer cells were assessed. In comparison to untreated cells
(upper left, Figure 3C), IL-27-treated cells exhibited a
more epithelial phenotype characterized by a markedly
more cohesive and organized appearance of the cells in a
cobblestone monolayer formation (lower left, Figure 3C).
Suppression of STAT1 expression by siRNA prior to IL-
27 treatment resulted in a phenotype characterized by
elongated spindle-shaped, fibroblast-like cells that were
morphologically similar to untreated cells (lower mid-
dle, Figure 3C), while STAT1 siRNA single treatment
did not significantly affect the phenotype of untreated
cells (upper middle, Figure 3C). The addition of the STAT3
inhibitor (Stattic) did not demonstrate marked morphologic
changes in A549 cells when compared to IL-27- treated
or -untreated cells (lower right and upper right, Figure 3C).
These findings suggest that STAT1 activation is the do-
minant pathway by which IL-27 mediates polarization of
NSCLC cells towards an epithelial phenotype.
IL-27 promotes expression of epithelial markers through
a STAT1 dominant pathway
EMT results in cellular changes associated with alter-
ations in expression of EMT markers [35]. To determine
if the STAT1-dependent IL-27 effect on cell morphology
correlated with changes in the EMT marker expression,
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Figure 3 Acquisition of a more epithelial phenotype by inhibition of STAT1 expression in IL-27 treated cells. (A) A549 cells were
transfected with a non-targeting control or STAT1 siRNAs (40 nM) for 6 hours prior to IL-27 (50 ng/mL) exposure for 15 or 30 minutes. Activated
and total amounts of STAT1 and STAT3 proteins were detected by Western blot. GAPDH was used as a loading control. (B) Stattic (7.5 nM) or its
diluent (DMSO) was added to A549 cells for 1 hour prior to IL-27 (50 ng/mL) exposure for 15 or 30 minutes. Activated and total amounts of STAT1
and STAT3 proteins were detected by Western blot. (C) After transfection with STAT1 siRNA (40 nM) for 6 hours or Stattic (7.5 nM) pre-treatment
for 1 hour, A549 cells were exposed to IL-27 (50 ng/mL) for 24 hours. Morphologic changes were documented and photographed by phase
contrast microscopy (50 × magnification). Scale bar, 100 μm.
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pression of E-cadherin and γ-catenin (epithelial phenotype),
and N-cadherin and vimentin (mesenchymal phenotype).
Snail, a transcriptional repressor of E-cadherin and a key
regulator of EMT was also examined [36,37]. Amounts of
the activated and total STAT1 and STAT3 proteins were
measured along with the EMT markers. IL-27 treated cells
showed increased expression of epithelial markers (E-cad-
herin and γ-catenin) and decreased expression of mesen-
chymal markers (N-cadherin and vimentin) compared to
untreated cells (Figure 4). In addition, the expression of
Snail protein was remarkably reduced by IL-27 treatment.
These data suggest that IL-27 induces MET.
Next, we examined whether IL-27 induces MET through
STAT pathways by blocking STAT1 and STAT3 pathwaysusing STAT1 siRNA or STAT3 inhibitor, Stattic, respect-
ively. As shown in Figure 4, pretreatment with STAT1
siRNA dramatically inhibited expression of T-STAT1, re-
sulting in complete inhibition of STAT1 phosphorylation.
Pretreatment with STAT1 siRNA before IL-27 exposure
resulted in increased Snail expression, decreased expres-
sion of epithelial markers (E-cadherin and γ-catenin), and
up regulation of mesenchymal marker (vimentin) com-
pared to treatment with IL-27 alone. STAT1 siRNA me-
diated down regulation of E-cadherin expression was
partially inhibited by the combined treatment with Stat-
tic and STAT1 siRNA given the increased E-cadherin
expression when comparing IL-27 + STAT1 siRNA vs.
IL-27 + STAT1 siRNA + Stattic groups (Figure 4). These



























































Figure 4 Increased expression of epithelial and decreased
expression of mesenchymal markers by a dominant STAT1
pathway. After transfection with STAT1 siRNA (40 nM) for 6 hours or
Stattic (7.5 nM) pre-treatment for 1 hour, A549 cells were exposed to
IL-27 (50 ng/mL) for 24 hours. Proteins responsible for the epithelial
phenotype (E-cadherin and γ-catenin) and the mesenchymal phenotype
(N-cadherin and vimentin) were detected by Western blot. Changes in
Snail levels were also demonstrated by Western blot. Activated and total
amounts of STAT1 and STAT3 were also detected, and GAPDH was used
as a loading control. Densitometric measurements of the bands were
taken using Image J1.45o. The values above the figures represent
relative density of the bands normalized to GAPDH.
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pected, the total amount of STAT3 protein (T-STAT3) was
not changed by Stattic, an inhibitor of STAT3 phospho-
rylation, but STAT3 phosphorylation was remarkably de-
creased (Figure 4). When compared to treatment with
IL-27 alone, pretreatment with Stattic before IL-27 stimula-
tion did not affect expression of epithelial markers (E-cad-
herin and γ-catenin) and mesenchymal marker (vimentin),
suggesting that STAT1 pathway plays a critical role in the
IL-27 mediated regulation of EMT.
Interestingly, there was no significant change in the ex-
pression of mesenchymal marker, N-cadherin, by STAT1
inhibition (STAT1 siRNA pretreatment) and the reducedexpression of N-cadherin by IL-27 was reversed by STAT3
inhibition (pretreatment with STAT3 inhibitor) (Figure 4),
indicating that the decreased expression of N-cadherin by
IL-27 may be mediated by STAT3 activation. The de-
creased expression of Snail by IL-27 was not reversed by
inhibition of STAT3 activation.
The mechanism driving the differential effect of IL-27 on
the two mesenchymal markers (N-cadherin and Vimentin)
is unclear as selective inhibition of STAT1 or STAT3 did
not elucidate a clear mechanism (Figure 4). Instead, there
was suggestion that STAT3 may be involved in N-cadherin
expression (Figure 4). Although N-cadherin is considered a
mesenchymal marker, its function may be more complex
as other studies have shown that repression of N-cadherin
is required for epithelial to mesenchymal transition in
some instances such as neural crest migration [34,38].
However, the overall effect with IL-27 stimulation in our
study was promotion of mesenchymal to epithelial transi-
tion. The impact of N-cadherin and STAT3 in this process
is unclear.
Overall, these results suggest that the STAT3 pathway
is not critically involved in the IL-27 mediated promo-
tion of epithelial marker expression. In summary, STAT1
appears to be the dominant pathway by which IL-27
promotes the expression of epithelial markers.
Of note, the reciprocal increase in P-STAT3 compared
to control with inhibition of STAT1 by siRNA seen in
Figure 3A is not demonstrated in Figure 4. These are
two different experiments where the duration of IL-27
stimulation and time point for measurement of P-STAT3
expression are entirely different for the two figures.
IL-27 inhibition of in vitro cell migration is mediated by a
STAT3-independent and STAT1-dependent pathway
To further evaluate phenotypic changes associated with
IL-27- epithelial marker expression beyond morphologic
appearance, we examined in vitro cell migration, a defin-
ing feature of the mesenchymal phenotype, by creating a
scratch or wound in a confluent monolayer of NSCLC
cells and evaluating wound closure as a result of cell mi-
gration. Borders of the wound were marked by solid
black lines. We expected IL-27 to inhibit cell migration
through STAT1 pathway. Indeed, A549 cells treated with
IL-27 showed only poor migration into the border line
(lower right, Figure 5A) whereas untreated cells displayed
rapid migration after 24 hours of IL-27 treatment (lower
left, Figure 5A). Next, we examined whether the inhibitory
effect of IL-27 on migration is related to STAT pathways
using STAT1 siRNA and STAT3 inhibitor, Stattic. Again,
whereas untreated cells demonstrated rapid cell migra-
tion toward each other with partial closing of the gap
between the solid black lines (upper left, Figure 5B), IL-27
treated cells showed remarkably decreased cell migration
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Figure 5 Inhibition of in vitro cell migration dependent upon STAT1 activation. (A) A549 cells were treated with IL-27 (50 ng/mL) at 60 ~
70% confluency for 24 hours and a scratch was created in the cell monolayer. The same fields were observed for cell migration using phase
contrast microscopy after 24 hours of IL-27 treatment. (B) The scratch technique was utilized to measure cell migration for A549 cells that were
transfected with STAT1 siRNA (40 nM) for 24 hours prior to with or without IL-27 (50 ng/mL) exposure. (C) The motility assay was employed to
measure cell migration after Stattic (7.5 nM) pre-treatment for 1 hour prior to IL-27 exposure (50 ng/mL), and changes in cell migration were
observed for 60 hours. Scale bar, 200 μm. (D and E) Cell migration evaluated using transwell chambers. A549 sells transfected with STAT siRNAs
for 24 hrs, control siRNA-transfected or untreated cells (D) followed by 1 hour of Stattic treatment (E) were plated 24 h after treatment with IL-27
on 96-well transwell plates. After 48 hours, cells that migrated through the pores to the under surface of the membrane and bottom wells were
labeled with Calcein-AM. Migration rate was calculated using fluorescence as described in Materials and Methods.
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compared to untreated cells (lower left, Figure 5B).
However, pretreatment with STAT1 siRNA prior to IL-
27 exposure caused a marked increase in cell migration
compared to untreated cells, and reversed the inhibitory
effect of IL-27 on cell migration as demonstrated by the
near complete wound closure between the black lines(lower right, Figure 5B), suggesting that STAT1 is required
for the inhibitory effect of IL-27 on cell migration. We
also evaluated the inhibition of the STAT3 pathway before
IL-27 exposure using a STAT3 inhibitor, Stattic. IL-27-
treated cells still maintained a large gap between the solid
black lines (upper right, Figure 5C) when compared to un-
treated cells that closed the gap created by the scratch
Kachroo et al. Journal of Experimental & Clinical Cancer Research 2013, 32:97 Page 10 of 14
http://www.jeccr.com/content/32/1/97after 60 hours of IL-27 treatment (upper left, Figure 5C).
The addition of the STAT3 inhibitor did not significantly
affect the inhibitory effect of IL-27 on migration (lower
right, Figure 5C), suggesting that IL-27 mediated inhib-
ition of cell migration may not be dependent on STAT3
activation.
Cell migration was further studied using the transwell
chamber migration assay in which the results were con-
sistent with scratch/wound assay findings. The addition
of IL-27 inhibited transwell cell migration (Figure 5D).
Treatment with STAT1 siRNA with or without IL-27
significantly increased transwell cell migration compared
to control siRNA group (Figure 5D). As such, STAT1
siRNA prevented IL-27 mediated inhibition of cell mi-
gration. In contrast, the addition of Stattic showed a sig-
nificant inhibition of cell migration (Figure 5E). Taken
together, our results demonstrate that IL-27 inhibits
in vitro cell migration via a STAT1 dependent mechan-
ism and that STAT3 does not appear to be essential in
the inhibitory effect.
IL-27-mediated inhibition of angiogenic factors is
STAT1-dependent
Tumor growth and metastasis are integrally dependent
on production of angiogenic factors and angiogenesis
[39-41]. Vascular endothelial growth factor (VEGF) is well
known potent angiogenic factor [42]. In addition to VEGF,
IL-8/CXCL8 and CXCL5 have been identified as import-
ant pro-angiogenic proteins in human NSCLC [43,44]. It
has previously been shown that IL-27 has anti-angiogenic
activity by down regulating the expression of VEGF, IL-8/
CXCL8 and CXCL5 in human multiple myeloma cells [3].
In this study, we examined the production of pro-
angiogenic factors, VEGF, IL-8/CXCL8, and CXCL5, to
determine the effects of IL-27 on angiogenesis in human
lung cancer.
STAT1 and STAT3 are known to have opposing roles
in VEGF regulation. For example, STAT1 has been shown
to be a negative regulator of VEGF and angiogenesis
[16,45,46]. In contrast, STAT3 transactivation with other
factors is required for full induction of the VEGF promoter
in cancer cells [47]. Similarly, STAT1 is required for inhib-
ition of IL-8 expression mediated by other cytokines [48].
Constitutive activation or knockdown of STAT3 has been
shown to up regulate or suppress IL-8 production in hu-
man melanoma cells, respectively [49]. The role of STAT1
and STAT3 pathways in the production of CXCL5 in can-
cer has not been well studied.
On this basis, the expression of angiogenic factors were
measured in A549 cells by ELISA after being exposed for
24 hours to IL-27 alone or after being pre-treated with
STAT1 siRNA or STAT3 inhibitor, Stattic. Our results
demonstrate that the inhibition of STAT1 by siRNA in
A549 cells led to increased production of VEGF, IL-8 andCXCL5 (Figure 6A, 6C, and 6E) while the suppression of
STAT3 activation caused reduced secretion of the pro-
angiogenic factors (Figure 6B, 6D, and 6F). IL-27 treated
cells showed statistically significant decrease in expression
of VEGF, IL-8/CXCL8, and CXCL5 compared to untreated
cells (Figure 6A, 6C, and 6E, respectively). Inhibition of
the STAT1 pathway by pretreatment with STAT1 siRNA,
but not control siRNA, reversed the IL-27 mediated de-
creased expression of VEGF, IL-8/CXCL8, and CXCL5,
resulting in increased levels of these pro-angiogenic factors
to levels significantly higher than untreated controls.
The impact of the STAT3 pathway was also studied by
the addition of Stattic to the IL-27-treated cells. Pretreat-
ment with the inhibitor of STAT3 activation did not re-
verse the inhibitory effect of IL-27 on the production of
VEGF, IL-8/CXCL8, and CXCL5, but rather led to further
decrease in the production of IL-8/CXCL8 when com-
pared to IL-27 alone (Figure 6B, 6D, and 6F), suggesting
that IL-27 mediated inhibitory effect on the production of
pro-angiogenic factors associated with angiogenesis is in-
dependent of STAT3.
Inhibition of both STAT1 and STAT3 activation also
reversed the reduction of IL-8 and CXCL5 by IL-27
treatment as demonstrated by the significantly increased
expression compared to IL-27 alone (Figure 6D and 6F).
The combined STAT1 and STAT3 inhibition effect of re-
ciprocal increased IL-8 and CXCL5 levels did not impact
VEGF (Figure 6B). These results suggest that STAT1-
dependent inhibitory effect of IL-27 on the production
of VEGF may also require STAT3 activation.
Overall, our findings support that STAT1, but not
STAT3, plays a primary role in inhibition of pro-angiogenic
factor production in human lung cancer by IL-27 treat-
ment. Furthermore, inhibition of STAT1 results in augmen-
tation of pro-angiogenic factors beyond the basal level
possibly due to increased STAT3 activation in addition to
STAT1 inhibition as shown in Figure 3A. Our data suggests
that the impact of basal STAT1 expression may regulate
STAT3 activation to control angiogenesis.Discussion
Epithelial to mesenchymal transition and angiogenesis have
emerged as integral processes in promoting carcinogenesis
[50]. The change from epithelial to mesenchymal pheno-
type has been associated with tumor invasion, metastasis,
and unfavorable prognosis [51]. The role of STAT path-
ways in regulating EMT during carcinogenesis and em-
bryogenesis has been described in a limited number of
studies. For example, STAT1 and STAT5 have been shown
to be involved in regulating EMT during renal tubule for-
mation and in mammary gland growth and epithelial dif-
ferentiation, respectively [52,53]. In cancer, STAT3 has
been implicated in EGF-mediated EMT in ovarian cancer





























































































































































































































Figure 6 Down-regulation of angiogenic factors and up-regulation of angiostatic factors by STAT1-dependent pathway. (A-F) Protein
concentrations of VEGF (A, B), IL-8/CXCL8 (C, D), CXCL5 (E, F) secreted by A549 cells were measured by ELISA. A549 cells were either transfected
with STAT1 siRNAs (40 nM) or control siRNA for 24 hours and further treated with or without Stattic (7.5 nM) for 1 hour followed by IL-27 (50 ng/mL)
treatment for 24 hours. The cell culture supernatants were used for ELISA. * p vs. no treatment, ** p vs. IL-27 by student t- test.
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genesis in murine fibrosarcoma tumor cells [16].
Epithelial and mesenchymal marker expression is known
to be important in EMT. Factors such as E-cadherin, cate-
nins, vimentin, and snail have all been correlated with clin-
ical and pathological features in non-small-cell lung cancer
[54-56]. Transcriptional repression of E-cadherin by Snail
is closely correlated with EMT and the loss of E-cadherin
expression is a hallmark of EMT [57]. The expression of
E-cadherin and catenins is reduced in NSCLC [55,56].
In addition, vimentin is over-expressed in many epithe-
lial cancers, including lung cancer, and its over expres-
sion in cancer correlates with tumor growth, invasion,
and poor prognosis [58].
IL-27 has been shown to have non-immune antitumor
effects in lung cancer that include suppression of COX-2
and PGE2, reduction of vimentin levels, and inhibition
of cell migration and invasion [27]. This study showed
that IL-27 treatment in lung cancer cells led to increased E-
cadherin expression and decreased expression of vimentinand Snail with inhibition of cell migration by suppression
of cyclooxygenase-2-mediated activities [27].
The importance of IL-27 in modulating EMT through
the STAT pathways is poorly understood in carcinogen-
esis. To our knowledge, there have been no studies that
have described MET as an anti-tumor mechanism of IL-
27. In our study, we hypothesized that IL-27 inhibits EMT
and angiogenesis through STAT dependent pathways.
Our results revealed that IL-27-treated lung cancer
cells show increased epithelial marker (E-cadherin and
γ-catenin), decreased Snail (transcriptional repressor of E-
cadherin), and decreased mesenchymal marker (N-cadherin
and vimentin) expression. In addition, IL-27 treatment sup-
pressed in vitro cell migration. The ability of IL-27 to pro-
mote MET and inhibit cell migration was abolished by
inhibition of the STAT1 pathway, but not the STAT3 path-
way, with the exception of N-cadherin expression. The im-
pact of N-cadherin and STAT3 in this process is unclear.
Overall, our findings suggest that IL-27 promotes MET
and the increased expression of epithelial marker proteins
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STAT1 dependence is a novel anti-tumor mechanism of
IL-27, which has not been previously described.
Our results support the body of evidence that STAT1
is associated with tumor suppressive properties, such as
inhibition of angiogenesis, tumor growth and metastasis
as well as promotion of apoptosis [12,16]. The role of
STAT3 in IL-27 regulation of EMT is not well understood.
In present study, the inhibition of STAT3 activation did
not reverse the increased expression of epithelial markers
(E-cadherin and γ-catenin) and the reduced expression of
mesenchymal marker (vimentin) and Snail by IL-27, and
STAT3 activation was not required for the inhibition of
cell migration by IL-27. Interestingly, the inhibition of
STAT1 activation led to increased STAT3 activation in IL-
27 treated lung cancer cells whereas inhibition of STAT3
activation alone did not significantly impact STAT1 ex-
pression. The current study does not provide a mechan-
ism by which inhibition of STAT1 led to increased STAT3
activation. However, similar to our results, previous stud-
ies have demonstrated that STAT1- deficient cells showed
increased STAT3 activation [59-61]. Potential mechanisms
by which STAT1 may directly inhibit STAT3 include com-
petition for receptor docking sites, promoters of target
DNA sequences, and/or binding cofactors. The receptor
docking site is a prerequisite for activation by tyrosine
phosphorylation and STAT3 can be phosphorylated by re-
ceptor bound tyrosine kinases [62,63]. In fact, it has been
shown that STAT1 suppresses STAT3 tyrosine phosphor-
ylation that mediates downstream signaling of other cyto-
kine receptors [60]. Thus it appears likely that STAT1
suppresses IL27-mediated STAT3 activation at least in
part by competing for the STAT docking site within the
IL-27 receptor cytoplasmic domain.
Our results also demonstrated that the inhibition of
STAT1 pathway in IL-27 treated cells resulted in aug-
mented cell migration and increased production of pro-
angiogenic factors (VEGF, IL-8, and CXCL-5) compared
to untreated cells. These findings may be due to the en-
hanced STAT3 activation in the setting of inhibition of
STAT1 activation. Activated STAT3 has been shown to play
an important role in oncogenic transformation and progres-
sion in many human cancers [13-15,17-20]. STAT3 has
been shown to regulate cell migration, motility and inva-
sion [64-66] and induce VEGF expression [18]. The anti-
angiogenesis properties of IL-27 in tumor models have been
described previously. It has been shown that anti-tumor
and anti-angiogenic activities of IL-27 in murine melanoma
tumors [5]. Cocco et al. described anti-angiogenic proper-
ties of IL-27 in a multiple myeloma tumor model [3]. How-
ever, these studies did not define the mechanism of IL-27
mediated inhibition of angiogenesis. The augmented cell
migration and promotion of angiogenesis factors may be
due to the reciprocal increase of STAT3 activation in thesetting of STAT1 inhibition. This hypothesis of STAT1 and
STAT3 interdependence is further supported by other
reports using a genomic technique to map transcriptional
factor binding sites and identified STAT3 as a direct tran-
scriptional target of STAT1 [67]. It has also been shown
that STAT3 was activated in a sustained strong manner in
STAT1 knock-out murine fibroblasts [60,68]. On this basis,
basal STAT1 activation may be required in repressing
STAT3 activation.
Cytokines, such as IL-27, that possess divergent func-
tions may play a pivotal role in influencing immune regu-
lation and carcinogenesis through differential STAT1 and
STAT3 activation and cross-regulation. There have been
limited reports understanding the regulation of EMT in
carcinogenesis through STAT pathways. Although the
anti-tumor properties of IL-27 have been described pre-
viously, our study describes a new mechanism by which
IL-27 inhibits EMT and angiogenesis through a STAT1
dominant pathway.
Conclusions
We report that IL-27-mediated induction of MET and in-
hibition of angiogenic factors is STAT1-dependent, and
inhibition of STAT1 activity results in induction of a mes-
enchymal phenotype and angiogenic factors above basal
levels implicating an overwhelming STAT3 effect. These
findings suggest that STAT1 activation may play an im-
portant role in repressing STAT3 in lung carcinogenesis,
and suggest that better understanding of STAT signaling
by cytokines such as IL-27 may shed light to potential
new targets in cancer prevention and therapy.
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